Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTwP-HepB-Hib-IPV hexavalent vaccine
- Development stage
- Phase 3
- Lead developer
- Panacea Biotec
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The DTwP-HepB-Hib-IPV hexavalent vaccine is a fully liquid, combination pediatric vaccine designed to provide active immunization against six major childhood infectious diseases: diphtheria, tetanus, pertussis (whooping cough), hepatitis B, invasive diseases caused by Haemophilus influenzae type b (Hib), and poliomyelitis. It combines diphtheria and tetanus toxoids, whole-cell Bordetella pertussis (wP) organisms, recombinant hepatitis B surface antigen (HBsAg), Hib capsular polysaccharide conjugated to a carrier protein (such as tetanus toxoid), and inactivated poliovirus (IPV) strains (types 1, 2, and 3). By integrating the IPV component into the traditional pentavalent (DTwP-HepB-Hib) formulation, this hexavalent vaccine simplifies infant immunization schedules, reduces the number of required injections, improves compliance, and supports global polio eradication efforts.
- Brand names
- Shan6Shan-6Shan 6EasySix
- Other names
- DTwP-HepB-Hib-IPV vaccineDTwP-IPV-HB-PRP~T vaccinewP-IPV hexavalent vaccine
02
Targets
Diphtheria toxinPRR (Pattern recognition receptors)HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on DTwP-HepB-Hib-IPV hexavalent vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTwP-HepB-Hib-IPV hexavalent vaccine.